Medicare beneficiaries can now get brand-name GLP-1 weight loss medications for $50 a month under a new federal pilot program, a fraction of the retail prices that have kept the drugs out of reach for millions of older Americans. The Medicare GLP-1 Bridge program, administered by the Centers for Medicare & Medicaid Services under Dr. Mehmet Oz, launched this week and is set to run through December 31, 2027.
The covered drugs, Eli Lilly's Foundayo tablets and Zepbound KwikPens, along with Novo Nordisk's Wegovy injections and tablets, carry list prices that can run hundreds of dollars a month at higher doses. Under the Bridge program, the flat $50 copay applies regardless of dosage.
It is a meaningful step toward affordability. But the program is temporary, eligibility is narrower than many beneficiaries may expect, and the $50 payments do not count toward deductibles or out-of-pocket maximums, details that deserve a closer look before anyone celebrates too loudly.
Eligibility hinges on body mass index and secondary health conditions. Beneficiaries with a BMI of 35 or higher qualify outright. Those with a BMI of 27 or higher can qualify if they also have an additional condition such as a prior heart attack, stroke, or prediabetes. The CMS website lists additional qualifying conditions, though the full roster has not been widely published.
Beneficiaries who already receive GLP-1 coverage through Medicare Part D for diagnoses like diabetes, sleep apnea, or fatty liver disease are excluded from the Bridge program, they are expected to continue under their existing coverage.
The Washington Examiner reported that approximately 4 million Medicare beneficiaries qualify under the Bridge program's eligibility criteria. That figure sits well below the broader population of overweight or obese Medicare enrollees. Juliette Cubanski, vice president and director of Medicare policy at KFF, a healthcare research nonprofit, noted that at least 10 million of the more than 70 million Americans enrolled in Medicare are overweight or obese, but only a narrower slice will have access through this program.
The New York Post placed the upper bound higher, reporting that up to 14 million Medicare recipients could be eligible. The gap between estimates reflects the uncertainty that still surrounds the program's reach.
The process starts with a healthcare provider. A beneficiary contacts their doctor, who sends a prescription for one of the four covered GLP-1 drugs to a pharmacy and completes a prior authorization form. Medicare itself, not the beneficiary's Part D insurer, subsidizes the cost.
That distinction matters. Because the subsidy flows from Medicare directly rather than through Part D, the $50 monthly payment does not count toward a beneficiary's annual deductible or out-of-pocket maximum. For seniors on fixed incomes who budget carefully around those thresholds, this is not a trivial wrinkle.
Oz declined to speculate on how many beneficiaries would enroll at launch, telling reporters that no reliable data exists to project demand. CMS Director of Medicare Chris Klomp offered only that the agency would "see where it scales over time."
The program's name tells you something about its ambitions and its limits. A bridge implies a destination on the other side. Whether one exists is an open question.
Federal law currently prohibits Medicare from covering drugs prescribed solely for weight loss. The Bridge program operates as a temporary workaround. Oz told the Associated Press that a permanent federal law authorizing the coverage is "not essential right now" but something "for Congress to debate amongst themselves." He added that CMS plans to "carefully track participation and outcomes" to inform any longer-term solution.
The pilot replaced, or, more precisely, followed, an earlier effort called the BALANCE voluntary pilot program. CMS indefinitely delayed BALANCE earlier this year after many Part D insurers refused to participate. That reluctance from private insurers is worth remembering. It signals that the insurance industry sees the cost math on broad GLP-1 coverage as deeply unfavorable.
A University of Chicago analysis cited by Breitbart found that expanded GLP-1 coverage would cost nearly $66 billion over ten years but save only $18 billion, a net $48 billion in new federal spending. Those numbers should give fiscal conservatives pause, even as the drugs deliver real health benefits to individual patients.
Gloria Dralla, a 78-year-old California resident, told the AP she lost approximately 40 pounds after purchasing lower-cost Wegovy in Europe. For her, the Bridge program means she can continue a treatment that has improved her life without traveling overseas to afford it.
"This drug should be made available at a reasonable price for everybody who's got weight loss problems."
Not everyone is as fortunate. Katie Smith, a 71-year-old Virginia resident, said she was quoted $700 a month for GLP-1 medications, a price she cannot afford. Smith has a BMI of 33 and a spinal cord injury from her twenties that severely limits her mobility and ability to exercise. She is unsure whether she has a qualifying secondary condition that would make her eligible for the Bridge program.
"I cannot tell you how frustrated I am. I have the drive and I have the willingness and I have the motivation, but I have not been able to lose weight in all the conventional ways."
Smith's situation illustrates the program's inherent tension. The eligibility criteria exclude some of the people who arguably need the drugs most, those whose physical limitations make conventional weight loss nearly impossible but who fall into the gap between a BMI of 27 and 35 without a listed secondary condition.
The Bridge program is scheduled to end after December 31, 2027. That creates a practical concern that goes beyond policy abstraction. Most GLP-1 users gain weight back when they stop taking the drug unless they have made significant lifestyle changes while on it. If the program sunsets without a successor, beneficiaries who enrolled and saw real results could find themselves right back where they started, only now with the added frustration of having tasted a solution they can no longer afford.
Oz acknowledged this uncertainty. He said CMS cannot decide what will happen long term "until we see some of the data." He also noted that other negotiations with drug companies to lower costs are ongoing, though he offered no specifics.
Congress, meanwhile, has shown no urgency to act. The legislative path to permanent Medicare coverage of weight loss drugs remains unclear, and the fiscal projections do not make the politics any easier.
The four medications included in the Bridge program are all FDA-approved for weight loss:
Retail prices for these drugs range from roughly $199 to $699 per month, sometimes higher at elevated dosages. The $50 flat rate represents a dramatic reduction, one made possible by what the New York Post described as a Trump administration "most favored nation" drug pricing deal.
The Bridge program deserves credit for doing something concrete. After years of hand-wringing about drug prices and obesity, CMS found a mechanism to get proven medications to cash-strapped seniors at a price most can manage. Oz framed the cost barrier plainly: "The sheer cost of these medications is a huge barrier to access. That ends today."
But the program also raises the kind of questions conservatives should press hard on. What is the legal and regulatory authority under which CMS is operating this program, given that Congress has never authorized permanent Medicare coverage of weight loss drugs? How will the government absorb the cost if enrollment scales rapidly? And what happens to millions of beneficiaries who build a medical regimen around a program that expires in eighteen months?
Private insurers already looked at the numbers and walked away from the BALANCE pilot. That is not a vote of confidence in the long-term fiscal sustainability of broad GLP-1 coverage. A $48 billion net cost over a decade is real money, money that comes from somewhere, which in this case means taxpayers.
The drugs work. The need is real. But a temporary program that sidesteps Congress, excludes payments from deductible calculations, and carries no clear path to permanence is not a solution. It is, at best, exactly what its name says: a bridge. The question is whether anyone is building anything on the other side, or whether Washington is just kicking the can down the road at $50 a month.
